Conclusion
This meta-analysis demonstrated the efficacy of HER2-targeted ADCs in GC
and GEJC patients as second- and later-line treatments. Patients with
HER2 overexpression benefitted more from these novel drugs than patients
with low HER2 expression. Regarding safety, the high incidence of grade3
and above AEs is worthy of attention. However, given the currently
limited clinical data, further validation is needed in larger-scale RCTs
in the future.